Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
28.24
-1.75 (-5.84%)
At close: Oct 30, 2026, 4:00 PM EDT
28.43
+0.19 (0.67%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Harrow Revenue
Harrow had revenue of $70.66M in the quarter ending June 30, 2026, with 10.85% growth. This brings the company's total for the last twelve months to $275.59M, up 21.05% year-over-year. In the year 2025, Harrow had annual revenue of $272.30M with 36.41% growth. That makes Harrow the 15,121st largest company in the world by revenue and 2,670th in the United States.
Revenue (ttm)
$275.59M
Revenue Growth
+21.05%
P/S Ratio
3.84
Revenue / Employee
$738,858
Employees
373
Market Cap
1.06B
Revenue by Segment
- Branded 195.76M 71.9%
- Compounding 76.55M 28.1%
Fiscal year ended Dec 31, 2025 See the full Harrow breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 272.30M | 72.69M | 36.41% |
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
| Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
| Dec 31, 2018 | 41.37M | 14.60M | 54.52% |
| Dec 31, 2017 | 26.77M | 6.83M | 34.26% |
| Dec 31, 2016 | 19.94M | 10.23M | 105.25% |
| Dec 31, 2015 | 9.72M | 8.06M | 485.30% |
| Dec 31, 2014 | 1.66M | -8.34M | -83.40% |
| Dec 31, 2013 | 10.00M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.52B |
| Trulieve Cannabis | 1.14B |
| ANI Pharmaceuticals | 978.38M |
| Collegium Pharmaceutical | 808.21M |
| Pacira BioSciences | 746.16M |
| Amphastar Pharmaceuticals | 730.02M |
| Alvotech | 494.61M |
| Ironwood Pharmaceuticals | 389.32M |
HROW News
- 4 days ago - Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 - GlobeNewsWire
- 25 days ago - Harrow Closes Acquisition of TYRVAYA® - GlobeNewsWire
- 4 weeks ago - Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO - GlobeNewsWire
- 7 weeks ago - Harrow Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 weeks ago - Leerink bullish on Harrow, initiates with an Outperform - TheFly
- 7 weeks ago - Harrow initiated with an Outperform at Leerink - TheFly
- 1 month ago - Harrow to Participate in Three Investor Conferences in September - GlobeNewsWire
- 2 months ago - Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - GlobeNewsWire